About Us
Cornerstone Robotics (CSR) is an innovative surgical robotics unicorn driven by the vision of leading medical innovations for a healthier world. We advance surgical care with cutting-edge robotic systems to make high-quality healthcare more accessible and efficient globally. With three global R&D hubs and six business centers worldwide, we have established a 30,000-square-meter manufacturing facility in China. Developed entirely in-house, the Sentire® Endoscopic Surgical System has successfully completed multicenter clinical trials in China and the United Kingdom and has received regulatory approvals in China, the European Union, and Singapore. Indicated for key specialties including general surgery, gynecology, thoracic and urology, the Sentire® System provides advanced minimally invasive surgical solutions to healthcare professionals worldwide, helping expand access to high-quality surgical care and improve patient outcomes globally.
Company History
2019
September
Cornerstone Robotics was officially established.
2020
August
Completed the Proof-of-Concept.
December
Successfully completed dozens of laboratory assessments on cadavers and animal models in Hong Kong.
2021
June
Surgical robot prototype successfully tested in porcine model in Shenzhen, China.
November
Completed Series B financing round of over USD 75 million.
The total amount of financing raised to date is approximately USD 120 million.
2022
June
Featured in the showcase of outstanding enterprises for the 25th Anniversary of the Hong Kong Handover and conducted technology demonstration for China's national leaders.
August
Completed the first human clinical trials in urology and general surgery in Hong Kong.
2023
June
Completed Series B+ financing round of over US$90 million.
December
Successfully completed a multi-center human clinical trial.
2024
June
Formed partnership with the Chinese University of Hong Kong, Shenzhen (CUHK-SZ) Medical School to build a world-class surgical robotics training program.
September
CSR's first robotic surgical system, Sentire®, registration approval by China's National Medical Products Administration (NMPA).
December
CSR's first robotic surgical system, Sentire®, registration approval by China's National Medical Products Administration (NMPA).
2025
January
Completed a Series C funding round of over USD 70 million to support the acceleration of CSR's R&D and global commercialization plans.
May
Starting human clinical trials in the United Kingdom.
July
Signed a tripartite strategic cooperation memorandum with the National Health Insurance Group of Singapore and the Lee Kong Chian School of Medicine at Nanyang Technological University.
November
Closes New Financing Round of Approximately USD 200 million.
2026
May
Sentire® received EU CE (MDR) and Singapore HSA certifications, covering four major specialties: general surgery, gynecology, thoracic and urology.
Corporate Culture
Our Mission
Forging accessibility and efficiency in robotic surgery and delivering high-quality healthcare to all.
Our Vision
Lead medical innovations for a healthier world.
Cornerstone Robotics (CSR) is dedicated to delivering accessible surgical systems that allow patients around the world to benefit from the high standards of care.
